Joint Research on Early Non-Destructive Prediction of Human iPSC Differentiation Efficiency Using Image Analysis and Machine Learning Published in Scientific Reports
Epistra Inc. (Tokyo) has jointly developed a novel method with the Center for iPS Cell Research and Application (CiRA) at Kyoto University that combines cell image analysis and machine learning. This method enables early, non-destructive prediction of differentiation efficiency from human iPSCs to muscle stem cells (MuSCs). The research findings were published online in Scientific Reports on July 23, 2025.
Overview and Results
Human iPSCs have the ability to differentiate into various cell types and hold promise for applications in regenerative medicine and drug discovery. The “stepwise differentiation induction method” is advantageous in terms of safety due to its high maturity, but variability in efficiency and extended culture periods (several months) remain challenges.
In this joint research, MuSC differentiation induction was used as a model system. By combining image analysis and machine learning, a method was developed to predict final differentiation efficiency early and non-destructively. While MuSC differentiation typically requires approximately 80 days, this method can predict efficiency at days 24-34, potentially contributing to efficient cell acquisition and accelerating regenerative medicine research.
Key advantages include avoiding destructive analytical methods, eliminating subjective expert evaluation, and enabling rapid and objective determination of differentiation status using images alone.
Paper Information
- Journal: Scientific Reports
- DOI: 10.1038/s41598-025-11108-5
Related Articles
Won Grand Prix in the 7th IP BASE AWARD Startup Category Hosted by the Japan Patent Office
On March 3, 2026, Epistra Inc. won the Grand Prix in the startup category at the '7th IP BASE AWARD' ceremony hosted by the Japan Patent Office.
Jikkenigaku Special Issue 'AI and Data-Driven Drug Discovery Research' Published — CTO Tsuzuki Authors Chapter on AI-Driven Drug Target Discovery
In 'Jikkenigaku Special Issue: AI and Data-Driven Drug Discovery Research' published by Yodosha, our CTO Taku Tsuzuki authored a chapter on AI-driven knowledge mining for drug target discovery.
Speaking Engagement: Delivered Keynote at the 10th Cell Manufacturing Kotozukuri Symposium
On March 4, 2026, CEO Yosuke Ozawa delivered a keynote speech on optimizing cell manufacturing processes using AI and robotics at the '10th Cell Manufacturing Kotozukuri Symposium' hosted by Osaka University.